<< TRAF6 protein can activate a cell signalling molecule associated with cancer | Medassets' web-based technology and consulting solutions to improve profitability of hospitals >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | हिन्दी | Русский | Svenska | Polski

Forest Laboratories to host a conference call for discussing the results of Daxas Phase III clinical trials

Published on August 28, 2009 at 5:09 AM · No Comments

Forest Laboratories, Inc. (NYSE: FRX), an international manufacturer and marketer of pharmaceutical products and Nycomed, a privately owned pharmaceutical company, will host a conference call at 7:15 AM EDT on Friday, August 28, 2009. Dr. Lawrence Olanoff, President and Chief Operating Officer of Forest Labs, Dr. Marco Taglietti, President of Forest Research Institute, Dr. Anders Ullman, Executive Vice President R&D of Nycomed and Professor Fernando Martinez from the University of Michigan will discuss the results of the Daxas® Phase III clinical trials that were published in The Lancet today.

The conference call will be webcast live beginning at 7:15 AM EDT on the Company's website www.frx.com and also on the website www.streetevents.com. Please log on to either website at least fifteen minutes prior to the conference call as it may be necessary to download software to access the call. A replay of the conference call will be available until September 11, 2009 at both websites and also by dialing 1-800-642-1687 (US investors) or +1-706-645-9291 (international investors), Conference Call ID 27580393.

http://www.nycomed.com/

Posted in: Drug Trial News

Tags: ,

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading